| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9273 | SC-66 Featured | SC-66 is an allosteric inhibitor of Akt; interferes with pleckstrin homology domain binding to PIP3 and facilitates Akt ubiquitination. |
|
| DC8333 | SC-79 Featured | SC-79 is an activator of Akt; binds to the pleckstrin homology domain of Akt. |
|
| DC11306 | Secorapamycin A(Seco Rapamycin) Featured | Seco-rapamycin(Secorapamycin A) is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.. |
|
| DC10193 | Seletalisib Featured | Seletalisib (UCB5857) is potent and selective PI3Kδ inhibitor with an IC50 of 12 nM. |
|
| DC11812 | SF-1126 | SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins. |
|
| DC10140 | SF2523 Featured | SF2523 is a highly selective and potent inhibitor of PI3K and BRD4with IC50 values of 16 and 241 nM for PI3Kα and BD1, respectively. |
|
| DC11796 | SN-32976 | SN-32976 is a novel, potent and selective class I PI3K and mTOR inhibitor with IC50 of 15.1/461/110/134/194 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR, respectively. |
|
| DC9311 | Serabelisib(TAK-117,INK1117,MLN1117) Featured | TAK-117(INK1117,MLN1117) is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity. |
|
| DCAPI1488 | Temsirolimus Featured | Temsirolimus is an inhibitor of ribosomal protein S6 phosphorylation and inhibits cell growth and clonogenic survival of cells in a concentration-dependent manner. |
|
| DC10150 | Tenalisib | Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and PI3Kγ inhibitor with IC50 values of 25 and 33 nM, respectively. |
|
| DC7516 | TG100-115 Featured | TG100115 is a PI3Kγ/δ inhibitor with IC50 of 83 nM/235 nM, with little effect on PI3Kα/β. Phase 1/2. |
|
| DC8652 | TGR-1202 hydrochloride(Umbralisib) | TGR-1202 hydrochloride is an orally available, next generation PI3Kdelta inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively. |
|
| DC8653 | TGR-1202(Umbralisib) Featured | TGR-1202 is an orally available, next generation PI3Kdelta inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively. |
|
| DC7321 | TGX221 Featured | TGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110β . |
|
| DC10055 | Akt-I-1,2 HCl Featured | The compound (Akt-I-1,2) inhibited both Akt1 and Akt2 with IC50 values of 2.7 and 21 μM respectively. |
|
| DC3117 | Torin2 Featured | Torin 2 is a highly potent and selective mTOR inhibitor with IC50 of 0.25 nM, and also exhibits potent cellular activity against ATM/ATR/DNA-PK with EC50 of 28 nM, 35 nM and 118 nM, respectively. |
|
| DC3118 | Torin1 Featured | Torin1 is a potent inhibitor of mTOR with IC50 of 2-10 nM. |
|
| DC10928 | UCB9608 Featured | UCB9608 is a Potent, Orally Bioavailable PI4KIIIβ Inhibitor. |
|
| DC10942 | UCT943 | UCT943 (UCT-943) is a potent, selective, next generation Plasmodium falciparum PI4K inhibitor with IC50 of 23 nM. |
|
| DC9899 | VO-Ohpic Featured | VO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM. |
|
| DC5181 | Voxtalisib Analogue Featured | Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. |
|
| DC8884 | Voxtalisib (XL765, SAR245409) Featured | Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. |
|
| DC10019 | VPS34 inhibitor 1 (Compound 19, PIK-III analogue) Featured | VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is a potent and selective inhibitor of VPS34 with an IC50 of 15 nM. |
|
| DC8650 | Vps34-IN-1 Featured | VPS34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks. |
|
| DC5088 | WYE125132 | WYE125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor |
|
| DC1068 | XL147 analogue(PI3K inhibitor X) Featured | XL147 analogue (SAR245408) is a selective and reversible class I PI3K inhibitor for wild type and mutant p110α with IC50 of 40 nM and 40 nM, respectively. |
|
| DC7343 | YM201636 Featured | YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α. |
|
| DC9343 | ZLN024 (hydrochloride) | ZLN024 Hcl is a novel AMPK allosteric activator; activated α1β1γ1 and α2β1γ1 by around 2–2.5 fold with an EC50 of about 1–2 uM. IC50 value: 1-2 uM (EC50) [1] Target: AMPK activator ZLN024 activated AMPK in L6 myotubes and stimulated glucose uptake and |
|
| DC1077 | ZSTK474 Featured | ZSTK474 is a potent pan-class I PI3K inhibitor with IC50 of 37 nM. |
|
| DC11906 | Parsaclisib Featured | Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies. |
|
